Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key ...
Liquid biopsy using ctDNA refines risk stratification for patients with residual cancer burden post-neoadjuvant therapy, ...
Combination therapy with nogapendekin alfa inbakicept and BCG achieved a 3-year DSS rate of 96% in BCG-unresponsive NMIBC ...
The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...
Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic ...
A promising trial reveals pumitamig combined with chemotherapy shows high response rates, suggesting potential benefits for ...
The blood-based test by Astrin Biosciences shows high sensitivity and specificity across cancer stages and subtypes, ...
Schmid detailed the rationale of combining pumitamig and chemotherapy and how the combination can aid patients in the first ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...
The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback